Kelulut Honey for Allergic Conjunctivitis and Dry Eye Symptoms
NCT07273747 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2025-12-09
Summary
The goal of this clinical trial is to learn if oral Kelulut honey works to improve eye symptoms in adults with allergic conjunctivitis. It will also look at how safe Kelulut honey is when taken as a daily supplement.
The main questions it aims to answer are:
1. Does oral Kelulut honey reduce itchy, red, watery eyes and dry eye symptoms in people with allergic conjunctivitis?
2. Does oral Kelulut honey improve tear film stability and the health of conjunctival goblet cells (special cells on the eye surface that help keep the eye moist)?
3. What side effects or medical problems do participants have when taking Kelulut honey?
Researchers will compare oral Kelulut honey to a honey-flavoured placebo syrup (a look-alike drink that does not contain Kelulut honey) to see if Kelulut honey is more effective than placebo for treating eye symptoms in allergic conjunctivitis.
Participants will:
1. Take either oral Kelulut honey or a honey-flavoured placebo syrup every day for 1 month
2. Continue their usual treatment for allergic conjunctivitis and dry eye disease as prescribed by their eye doctor
3. Attend clinic visits for eye check-ups, including tests of tear film stability, dry eye symptoms, and eye surface health
4. Answer questionnaires about their eye symptoms and how these affect their daily activities and vision-related quality of life
Participation is voluntary, and participants may stop taking part in the study at any time. Data collected up to the time they withdraw may still be used for research, but their routine medical care will not be affected
Conditions
- Dry Eye Symptoms
- Allergic Conjunctivitis of Both Eyes
Interventions
- DIETARY_SUPPLEMENT
-
Kelulut Honey 60 g Oral Supplement
Participants in this arm will consume two 30 g sachets of Kelulut honey once daily (total 60 g/day) for one month. The honey will be taken directly from the sachet without dilution, on an empty stomach, 30 minutes before breakfast. Participants will continue their usual treatment for allergic conjunctivitis and dry eye disease.
- DIETARY_SUPPLEMENT
-
Kelulut Honey 120 g Oral Supplement
Participants in this arm will consume four 30 g sachets of Kelulut honey daily (total 120 g/day) for one month. The daily dose will be divided into two administrations: two sachets before breakfast or lunch, and two sachets before dinner. The honey will be taken directly from the sachets without dilution, at least 30 minutes before meals. Participants will continue their usual treatment for allergic conjunctivitis and dry eye disease.
- OTHER
-
Honey-Flavoured Zero-Calorie Syrup (Placebo)
Participants in this placebo group will receive honey-flavoured zero-calorie syrup, pre-packaged in sachets identical to those used for the Kelulut honey. Each participant will consume two sachets per day, to be taken daily, once before breakfast, for one month duration. The syrup is to be taken directly from the sachets, without dilution, before meals.
Sponsors & Collaborators
-
Universiti Sains Malaysia
lead OTHER
Principal Investigators
-
Shahidatul Adha Dr, MD, MMed · Universiti Sains Malaysia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-09-17
- Primary Completion
- 2026-01-16
- Completion
- 2026-09-30
Countries
- Malaysia
Study Locations
More Related Trials
-
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis
NCT00445874 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
NCT01732757 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
NCT00836485 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis
NCT01272089 ·Status: COMPLETED ·Phase: PHASE4
-
Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
NCT00133627 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects
NCT00987272 ·Status: COMPLETED ·Phase: PHASE3
-
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
NCT01561521 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease
NCT05403827 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis
NCT03379311 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
NCT01479374 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
NCT00241319 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
NCT05969236 ·Status: COMPLETED ·Phase: PHASE1
-
Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye
NCT02219204 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
NCT02218489 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
NCT01470118 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Twinkle Eyez Supplementation in Improving Ocular Health and Immunity
NCT06574685 ·Status: COMPLETED ·Phase: NA
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
NCT01107405 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
NCT01743027 ·Status: COMPLETED ·Phase: PHASE3
-
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
NCT02308501 ·Status: COMPLETED ·Phase: PHASE4
-
Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
NCT03383276 ·Status: UNKNOWN ·Phase: PHASE1
-
Study Evaluating the Safety of KetoNaph Ophthalmic Solution in Healthy Volunteers
NCT01159015 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients
NCT06212973 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Olopatadine on Allergic Tear Mediators
NCT00609128 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Effectiveness of Auricular Acupuncture in Improving Dry Eye Symptoms in University Students
NCT06876077 ·Status: COMPLETED ·Phase: NA
-
Effects of Topical Insulin on Levels of Tear Inflammatory Mediators
NCT04877210 ·Status: UNKNOWN ·Phase: PHASE1